Bicycle Therapeutics Plc (BCYC) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Bicycle Therapeutics Plc  (NASDAQ: BCYC)
 

Bicycle Therapeutics Plc Growth Comparisons

Select each growth Category to receive further Information





BCYC Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 190.24 % 14.14 % 10.2 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) 5314.47 % -1.07 % -2.54 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 194.75 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 36.47 % 2.69 % 2.1 % 2.61 %
Revenue 5 Year Average Growth 47.52 % 7.52 % 8.67 % 13.63 %


BCYC's Growth Comparisons in III. Quarter 2026




Impressive surge in Bicycle Therapeutics Plc's Revenue in the third quarter 2026 by 190.24% from the same quarter a year ago, to 34 millions, appears to be a slow-down from Bicycle Therapeutics Plc's growth trends, but competes favorably to the 14.14% rise in the Major Pharmaceutical Preparations industry, and 10.2% improvement in the Healthcare sector. Comparing the third quarter sales growth, both Major Pharmaceutical Preparations industry and Bicycle Therapeutics Plc outperformed 10.9% overall market increase.

Company's sequential Revenue growth rate was impressive 5314.47% from the second quarter. Average yearly sales growth for Bicycle Therapeutics Plc is 47.52%, while S & P 500's average annual sales growth is 13.63% over the five years, including only Businesses with the third quarter 2026 financial reports.

BCYC Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Single reportable segment
203.16 %
3910.48 %
Total
190.24 %
5314.47 %


Growth Rates of BCYC's Income in the third quarter 2026


BCYC Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - 4.19 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) - -23.95 % -12.31 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) - 30.85 % 31.01 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) - -2.24 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change - 14.12 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - -16.85 % -38.84 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) - -26.31 % -63.29 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - 6.33 % 9.9 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) - -9.97 % -4.66 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - 14.58 % 8.91 % -28.64 %

BCYC Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - -17.47 % -39.18 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) - 21.94 % 11.48 % 27.07 %
Y / Y Net Income Change (Q3 TTM) - 5.05 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) - -10.2 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth - 14.16 % 9.09 % 23.95 %

BCYC's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - -31.09 % -38.84 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) - -35.27 % -63.29 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) - - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - -0.46 % 8.91 % -28.64 %



BCYC EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - -31.6 % -39.18 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) - 7.1 % 11.48 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) - 0.05 % 10.56 % 4.93 %
EPS Net 5 Year Avg. Change - 14.16 % 9.09 % 23.95 %



Bicycle Therapeutics Plc reported bottom-line of $ -0.15 in the third quarter, compare to $ -0.85 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -31.6%, while Healthcare sector decreased by -39.18%, and overall market improved by 90.69%.

The Company's sequential EPS growth rate was very impressive 5314.47% from the second quarter. Average yearly income per share growth for Bicycle Therapeutics Plc is 47.52%, while S & P 500's average annual income per share growth is 23.95% over the five years, including only Businesses with the third quarter 2026 earnings results.

BCYC Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - 26.04 % 44.7 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) - -29.98 % -42.72 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) - 12.35 % 19.45 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) - 3.58 % 5.9 % 15.75 %
Free Cash Flow 5 Year Avg. Change - 0.88 % 0.41 % 1.8 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) - - - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) -54.75 % 18.43 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) 15.09 % -21.14 % -19.33 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) -13.39 % 15.45 % 8.85 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) -16.58 % 1.84 % 0.98 % 23.05 %
Capital Expenditures 5 Year Avg. Change 14.39 % 7.88 % 8.63 % 14.2 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.